Delayed Paclitaxel-Trastuzumab-Induced Interstitial Pneumonitis in Breast Cancer
Open Access
- 1 April 2011
- journal article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 4 (1), 186-191
- https://doi.org/10.1159/000326063
Abstract
Pneumonitis is a rare but serious complication associated with paclitaxel and/or trastuzumab treatment. We report a 51-year-old female patient with locally advanced breast cancer who presented with shortness of breath, fever, dry cough and pulmonary infiltrates. She had been treated without complications for 10 weeks with paclitaxel (Taxol®) and trastuzumab (Herceptin®) as neoadjuvant therapy, with complete clinical and pathological response. Infections and cardiomyopathy were excluded as causes of her symptoms. Bronchoscopy and biopsy were performed and a diagnosis of drug-induced interstitial pneumonitis was made. After treatment with steroids, the patient showed a significant response in less than 24 h; she was discharged home without the need for oxygen less than 48 h after therapy initiation. Although no causative association could be found between either trastuzumab or paclitaxel and this patient’s pulmonary syndrome, the potential for such toxicity should be considered, especially as paclitaxel/trastuzumab is a vey common combination therapy for breast cancer.Keywords
This publication has 17 references indexed in Scilit:
- Fatal pneumonitis after treatment with docetaxel and trastuzumab.2009
- Trastuzumab (Herceptin)‐associated lung injuryRespirology, 2006
- Pulmonary toxicity from novel antineoplastic agentsAnnals of Oncology, 2005
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly ScheduleJournal of Clinical Oncology, 2005
- Drug-induced infiltrative lung disease.2001
- Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast CancerOncology, 2001
- Paclitaxel-Induced Cell-Mediated Hypersensitivity PneumonitisOncology, 1998
- Hypersensitivity reactions from taxol.Journal of Clinical Oncology, 1990